Sudheer Karnati, MD
Internal Medicine · Lufkin, TXNPI 1811186596
Payments from drug & device makers
Across 237 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$833
- Bayer$469
- Boehringer Ingelheim$414
- AstraZeneca$314
- Pfizer$266
- Lilly USA, LLC$263
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,22498%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $833 |
| Bayer | 23 | $469 |
| Boehringer Ingelheim | 22 | $414 |
| AstraZeneca | 13 | $314 |
| Pfizer | 15 | $266 |
| Lilly USA, LLC | 16 | $263 |
| Amgen | 16 | $223 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $179 |
| Astellas Pharma US Inc | 6 | $157 |
| E.r. Squibb & Sons, L.L.C. | 9 | $156 |
| Johnson & Johnson | 7 | $127 |
| Exact Sciences | 8 | $120 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| Sunovion Pharmaceuticals Inc. | 7 | $111 |
| Novartis | 5 | $88 |
| GSK | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Dexcom, Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $28 |
| Seqirus USA Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 2 | $24 |
| Merck | 1 | $18 |
| CMP Pharma, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
How this compares
$4,319 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $285,483 |
| EliquisApixaban | 225 | $196,336 |
| JardianceEmpagliflozin | 180 | $141,942 |
| FarxigaDapagliflozin Propanediol | 149 | $96,007 |
| RybelsusSemaglutide | 70 | $84,045 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $72,236 |
| MounjaroTirzepatide | 58 | $66,097 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 86 | $65,444 |
| XareltoRivaroxaban | 62 | $61,772 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $39,924 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $31,242 |
| JanuviaSitagliptin Phosphate | 44 | $26,305 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $22,743 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $18,107 |
| EntrestoSacubitril/Valsartan | 14 | $17,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $833 | $369,528322 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat, Tradjenta, Spiriva Respimat | $414 | $201,970274 claims |
| PfizerEliquis | $266 | $196,336225 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $314 | $112,244171 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $76 | $103,478164 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $114 | $70,761121 claims |
| Lilly USA, LLCMounjaro | $263 | $66,09758 claims |
| Johnson & JohnsonXarelto | $127 | $61,77262 claims |
| MerckJanuvia | $18 | $26,30544 claims |
| NovartisEntresto | $88 | $17,32914 claims |
| BayerKerendia | $469 | $8,76412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Lufkin
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.